Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the fiscal 2020 fourth quarter and full year on November 23, 2020, before market opening. A conference call at 8:00 a.m. ET will discuss these results and provide a business update. Investors can access the financial release via the Investor Relations section on the company's website. Twist Bioscience focuses on synthetic DNA manufacturing using a proprietary silicon platform, catering to various industries including healthcare and agriculture.
Twist Bioscience (NASDAQ: TWST) and Neogene Therapeutics have announced a strategic partnership to develop personalized T cell therapies for cancer. The collaboration combines Neogene's expertise in identifying tumor neo-antigens with Twist's synthetic DNA synthesis platform. Twist will create a specialized T cell receptor (TCR) library for Neogene, focusing on two cancer targets. The partnership aims to expedite the development of innovative cancer treatments and includes technology access fees, milestones, and royalties tied to preclinical and clinical outcomes.